DE69900648T2 - Dextrinhaltige mischung zur verhinderung von chirurgischen verklebungen - Google Patents
Dextrinhaltige mischung zur verhinderung von chirurgischen verklebungenInfo
- Publication number
- DE69900648T2 DE69900648T2 DE69900648T DE69900648T DE69900648T2 DE 69900648 T2 DE69900648 T2 DE 69900648T2 DE 69900648 T DE69900648 T DE 69900648T DE 69900648 T DE69900648 T DE 69900648T DE 69900648 T2 DE69900648 T2 DE 69900648T2
- Authority
- DE
- Germany
- Prior art keywords
- dextrin
- composition according
- composition
- adhesions
- aqueous formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 229920001353 Dextrin Polymers 0.000 claims abstract description 52
- 239000004375 Dextrin Substances 0.000 claims abstract description 52
- 235000019425 dextrin Nutrition 0.000 claims abstract description 52
- 206010060932 Postoperative adhesion Diseases 0.000 claims abstract description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 8
- 239000005017 polysaccharide Substances 0.000 claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000013011 aqueous formulation Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 4
- 102000005701 Calcium-Binding Proteins Human genes 0.000 claims description 4
- 108010045403 Calcium-Binding Proteins Proteins 0.000 claims description 4
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims description 4
- 229960001123 epoprostenol Drugs 0.000 claims description 4
- 229940014041 hyaluronate Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 150000003904 phospholipids Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- -1 glycosylaminoglycan Chemical class 0.000 claims description 2
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002357 osmotic agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 7
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 229920002177 Icodextrin Polymers 0.000 description 20
- 229940016836 icodextrin Drugs 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000004303 peritoneum Anatomy 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000011887 Necropsy Methods 0.000 description 3
- 208000031737 Tissue Adhesions Diseases 0.000 description 3
- 229920006318 anionic polymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 241000009120 Elymus fibrosus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 208000005646 Pneumoperitoneum Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229940099678 norco Drugs 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9810127.2A GB9810127D0 (en) | 1998-05-13 | 1998-05-13 | Prevention of surgical adhesions |
| US27271399A | 1999-03-19 | 1999-03-19 | |
| PCT/GB1999/001306 WO1999058168A1 (en) | 1998-05-13 | 1999-05-13 | Dextrin-containing composition for preventing surgical adhesions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69900648D1 DE69900648D1 (de) | 2002-01-31 |
| DE69900648T2 true DE69900648T2 (de) | 2002-07-04 |
Family
ID=26313653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69900648T Expired - Lifetime DE69900648T2 (de) | 1998-05-13 | 1999-05-13 | Dextrinhaltige mischung zur verhinderung von chirurgischen verklebungen |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1085920B1 (enExample) |
| JP (2) | JP3679710B2 (enExample) |
| CN (1) | CN1181894C (enExample) |
| AT (1) | ATE211002T1 (enExample) |
| AU (1) | AU740832B2 (enExample) |
| BR (1) | BR9911769B8 (enExample) |
| CA (1) | CA2331672C (enExample) |
| DE (1) | DE69900648T2 (enExample) |
| DK (1) | DK1085920T3 (enExample) |
| ES (1) | ES2165735T3 (enExample) |
| IL (2) | IL139283A0 (enExample) |
| NO (1) | NO312709B1 (enExample) |
| NZ (2) | NZ507832A (enExample) |
| PL (1) | PL194109B1 (enExample) |
| PT (1) | PT1085920E (enExample) |
| WO (1) | WO1999058168A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2363713A (en) * | 2000-06-21 | 2002-01-09 | Ml Lab Plc | Dextrin compositions |
| CA2392666C (en) * | 2000-01-21 | 2011-12-13 | Ml Laboratories Plc | Dextrin containing compositions for prevention of adhesions |
| GB0115505D0 (en) * | 2001-06-25 | 2001-08-15 | Britannia Pharmaceuticals Ltd | Prevention of surgical adhesions |
| US8252333B2 (en) * | 2006-01-26 | 2012-08-28 | Jorge Cueto-Garcia | Biodegradable, non-toxic biological adhesive for use in abdominal surgery |
| US8455001B2 (en) | 2007-02-06 | 2013-06-04 | Teijin Limited | Cellulose derivative and method for production thereof |
| DE102008005172A1 (de) * | 2008-01-19 | 2009-07-23 | Mike Ehrlich | Pharmazeutische Zusammensetzung zur Verhinderung von post-operativen Adhäsionen |
| EP2676682A1 (en) * | 2011-02-08 | 2013-12-25 | Jorge Cueto García | Thixotropic biological adhesive for use in internal body cavities |
| US20220265896A1 (en) * | 2019-08-01 | 2022-08-25 | Km Biologics Co., Ltd. | Tissue fibrosis inhibitor in which biocompatible polymer is used |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0207676B1 (en) * | 1985-06-22 | 1994-06-01 | M L Laboratories Plc | Polymers for use in continuous peritoneal dialysis |
| SE457933B (sv) * | 1987-07-06 | 1989-02-13 | Larsson Kare | Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion |
| SE8900586L (sv) * | 1989-02-21 | 1990-08-22 | Pharmacia Ab | Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader |
| US5093319A (en) * | 1989-10-31 | 1992-03-03 | Pfizer Hospital Products Group, Inc. | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions |
| EP0426368B1 (en) * | 1989-10-31 | 1995-01-04 | Howmedica Inc. | Compositions containing derivatives of chitin for preventing adhesion |
| US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| US5614515A (en) * | 1994-11-17 | 1997-03-25 | University Of Southern California | Lazaroid-based compositions and method for preventing adhesion formation using the same |
| US5807833A (en) * | 1995-06-07 | 1998-09-15 | University Of Southern California | Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device |
| CA2223590A1 (en) * | 1995-06-07 | 1996-12-19 | The University Of Southern California | Method for reducing or preventing post-surgical adhesion formation using 5-lipoxygenase inhibitors |
| JP3925955B2 (ja) * | 1996-04-26 | 2007-06-06 | 株式会社クラレ | 癒着防止材 |
| IN192791B (enExample) * | 1996-06-28 | 2004-05-22 | Johnson & Johnson Medical |
-
1999
- 1999-05-13 NZ NZ507832A patent/NZ507832A/xx not_active IP Right Cessation
- 1999-05-13 CN CNB998060836A patent/CN1181894C/zh not_active Expired - Lifetime
- 1999-05-13 PL PL99344536A patent/PL194109B1/pl unknown
- 1999-05-13 DE DE69900648T patent/DE69900648T2/de not_active Expired - Lifetime
- 1999-05-13 NZ NZ523994A patent/NZ523994A/en not_active IP Right Cessation
- 1999-05-13 EP EP99920952A patent/EP1085920B1/en not_active Expired - Lifetime
- 1999-05-13 CA CA002331672A patent/CA2331672C/en not_active Expired - Lifetime
- 1999-05-13 PT PT99920952T patent/PT1085920E/pt unknown
- 1999-05-13 DK DK99920952T patent/DK1085920T3/da active
- 1999-05-13 WO PCT/GB1999/001306 patent/WO1999058168A1/en not_active Ceased
- 1999-05-13 ES ES99920952T patent/ES2165735T3/es not_active Expired - Lifetime
- 1999-05-13 IL IL13928399A patent/IL139283A0/xx active IP Right Grant
- 1999-05-13 AU AU38336/99A patent/AU740832B2/en not_active Expired
- 1999-05-13 JP JP2000548018A patent/JP3679710B2/ja not_active Expired - Lifetime
- 1999-05-13 AT AT99920952T patent/ATE211002T1/de active
- 1999-05-13 BR BRPI9911769A patent/BR9911769B8/pt not_active IP Right Cessation
-
2000
- 2000-10-26 IL IL139283A patent/IL139283A/en not_active IP Right Cessation
- 2000-11-01 NO NO20005492A patent/NO312709B1/no not_active IP Right Cessation
-
2004
- 2004-09-21 JP JP2004273531A patent/JP4276601B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BR9911769B8 (pt) | 2021-06-22 |
| JP4276601B2 (ja) | 2009-06-10 |
| CA2331672C (en) | 2007-02-06 |
| NO20005492L (no) | 2001-01-12 |
| BR9911769A (pt) | 2001-02-06 |
| ES2165735T3 (es) | 2002-03-16 |
| DE69900648D1 (de) | 2002-01-31 |
| CN1181894C (zh) | 2004-12-29 |
| JP2005047929A (ja) | 2005-02-24 |
| EP1085920B1 (en) | 2001-12-19 |
| NO20005492D0 (no) | 2000-11-01 |
| AU740832B2 (en) | 2001-11-15 |
| EP1085920A1 (en) | 2001-03-28 |
| CA2331672A1 (en) | 1999-11-18 |
| NZ523994A (en) | 2004-11-26 |
| NZ507832A (en) | 2003-03-28 |
| PL344536A1 (en) | 2001-11-05 |
| JP2003528026A (ja) | 2003-09-24 |
| HK1034680A1 (en) | 2001-11-02 |
| BR9911769B1 (pt) | 2014-10-07 |
| PL194109B1 (pl) | 2007-04-30 |
| CN1300226A (zh) | 2001-06-20 |
| NO312709B1 (no) | 2002-06-24 |
| ATE211002T1 (de) | 2002-01-15 |
| JP3679710B2 (ja) | 2005-08-03 |
| IL139283A (en) | 2007-02-11 |
| AU3833699A (en) | 1999-11-29 |
| PT1085920E (pt) | 2002-06-28 |
| IL139283A0 (en) | 2001-11-25 |
| DK1085920T3 (da) | 2002-04-15 |
| WO1999058168A1 (en) | 1999-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69838614T2 (de) | Zusammensetzungen von Carboxypolysaccharid-Polyetherkomplexen zur Verwendung zum Vermindern chirurgischer Verwachsungen | |
| DE69013833T2 (de) | Zusammensetzung und methode zur verhütung von verklebungen zwischen körpergewebe. | |
| DE69631044T2 (de) | N,o-carboxymethylchitosan zur verhinderung operativ bedingter adhäsionen | |
| DE69233535T2 (de) | Ionisch vernetzte Karboxylgruppe enthaltende Polysaccharide zur Verhütung von Gewebeverklebung | |
| DE69738462T2 (de) | Bioresorbierbare medizinische Vorrichtungen aus oxidierten Polysacchariden | |
| DE69306114T2 (de) | Verwendung von in situ modifikation von alginat zur vorbeugung von gewebeadhäsion | |
| DE3854604T2 (de) | Antientzündungsmittel und zusammensetzungen. | |
| DE69828993T2 (de) | Kontrollierte abgabe von pharmazeutika in der vorderen augenkammer | |
| DE3321446C2 (de) | Verwendung von Chitosan zur Erzielung einer Hämostase, zur Inhibierung der Fibroplasie und zur Förderung der Geweberegeneration einer Wunde | |
| DE602004002908T2 (de) | Postchirurgische Antiadhäsionsschicht bestehend aus Carboxymethylchitosan und Carboxymethylcellulose und ihr Herstellungsverfahren | |
| DE69900648T2 (de) | Dextrinhaltige mischung zur verhinderung von chirurgischen verklebungen | |
| WO2003053452A1 (de) | Heparin-haltiges ophthalmikum | |
| DE68921002T2 (de) | Verfahren und mittel zur präventiven behandlung von chirurgischen adhäsionen. | |
| DE102005017845A1 (de) | Autosterile, antiseptische Kollagenzubereitungen, ihre Verwendung und Verfahren zu ihrer Herstellung | |
| US8642574B2 (en) | Surgical compositions for reducing the incidence of adhesions | |
| DE69622863T2 (de) | Verwendung von hydroxyethylstärke zur verhinderung postoperativer adhäsion und als träger für innenhohlräume | |
| EP2506858B1 (de) | Stärkederivatmischungen | |
| DE60111921T2 (de) | Dextrinhaltige zusammensetzung zur vermeidung von adhäsionen | |
| EP1579876B1 (de) | Zusammensetzung zur Adhäsionsprophylaxe | |
| HK1034680B (en) | Dextrin-containing composition for preventing surgical adhesions | |
| MXPA00011106A (en) | Dextrin-containing composition for preventing surgical adhesions | |
| DE102016008533A1 (de) | Arzneimittel | |
| WO2019134725A2 (de) | Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: INNOVATA PLC, NOTTINGHAM, NOTTINGHAMSHIRE, GB |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: INNOVATA LTD., NOTTINGHAM, NOTTINGHAMSHIRE, GB |